Phase II 'Proof of Concept' Study of TALL-104 (MHC Non-Restricted Cytotoxic T-Cell Line) and Imatinib Mesylate (Gleevec) in Chronic Myelogenous Leukemia in Chronic Phase.
Phase of Trial: Phase II
Latest Information Update: 02 Sep 2014
At a glance
- Drugs TALL 104 (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 01 May 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Apr 2012 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 02 Mar 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.